紫杉醇脂质体联合奥沙利铂治疗晚期非小细胞癌临床观察

The Observation of Paclitaxel Liposome Combined with Oxaliplatin in Treatment of Advanced Non-small Cell Carcinoma

目的:观察紫杉醇脂质体联合奥沙利铂治疗晚期非小细胞癌的临床疗效。方法:26例病理证实的晚期非小细胞癌患者用紫杉醇脂质体联合奥沙利铂治疗。紫杉醇脂质体135mg/m^2静滴,第1天,奥沙利铂总量130mg/m^2静滴,分第1、8天用。每例患者均完成2周期以上。化疗后予以疗效评定及毒副反应评定。结果:化疗后总有效率为44.1%,其中初治患者有效率为54.5%,复治患者总有效率为33.3%,两组比较有统计学意义。两组均无治疗相关性死亡,总的不良反应较轻。结论:紫杉醇脂质体联合奥沙利铂治疗晚期非小细肺癌,近期疗效确切,有效率较高,毒副作用较轻,患者可耐受。

Objective：To investigate the effects of paclitaxel liposome combined with oxaliplatin in treatment of advanced non-small cell carcinoma.Methods：26 cases of patients with advanced non-small cell carcinoma confirmed by Pathology were treated with paelitaxel liposome 135mg/m^2 IV days 1 ＆ 8 and oxaliplatin 130mg/m^2 IV days 1 ＆ 8.Each patient should complete no less than two cycles.The response and toxicity of chemotherapy was evaluated after treatment.Results：The overall response rate was 44.1%.As the first-line regimen the response rate was 54.5%,as the second-line regimen the response rate was 33.3%.there was statistically significant between the two groups. Furthermore,there were no treatment-related death, and the total adverse reactions were minor.Conclusions：Combination of chemotherapy with paclitaxel liposome and oxaliplatin is effective and safe in treatment of advanced non-small cell lung cancer.